Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relmada Therapeutics, Inc. (RLMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Relmada identifies itself in these documents as a Nevada corporation with common stock listed on the Nasdaq Capital Market under the symbol RLMD and principal offices in Coral Gables, Florida.
Through forms such as Form 8‑K, Relmada reports material events related to its business. Recent 8‑K filings describe topics including: written FDA feedback on planned Phase 3 registrational trials for NDV-01 in non-muscle invasive bladder cancer; preliminary nine‑month safety and efficacy data from the NDV-01 Phase 2 study; quarterly financial updates; an underwritten offering of common stock and pre-funded warrants; Nasdaq minimum bid price compliance matters; and amendments to executive employment agreements. These filings often incorporate press releases as exhibits and summarize key financial or clinical information referenced in company news.
Investors interested in capital structure and financing can review 8‑K disclosures regarding the terms of underwritten offerings, pre-funded warrants, and related legal opinions. Those focused on governance and compensation can examine filings detailing amended and restated employment agreements for executive officers, including changes to salary and severance provisions.
While this page emphasizes current and historical 8‑K reports, Relmada also files other periodic and registration statements, such as Forms 10‑Q, 10‑K, and S‑3, that contain more extensive financial statements, risk factor discussions, and descriptions of its NDV-01 and sepranolone development programs. Stock Titan enhances access to these documents by pairing them with AI-powered tools that help explain filing contents, highlight key sections, and make it easier to locate information on topics such as clinical trial plans, cash resources, listing status, and executive arrangements.
Relmada Therapeutics director and COO Paul Kelly reported receiving 828,000 stock appreciation rights tied to the company’s common stock. These rights were granted on December 12, 2025 with an exercise price of $4.06 and expire on December 12, 2035.
The stock appreciation rights vest in 16 equal quarterly installments starting March 12, 2026, so portions of the award become exercisable over time. After this grant, Kelly beneficially owns 828,000 derivative securities directly, linking part of his compensation to Relmada’s future share performance.
Relmada Therapeutics, Inc. reported an insider equity award to one of its directors. On 12/12/2025, the director received stock appreciation rights tied to 164,000 shares of common stock with a base price of
These stock appreciation rights begin vesting in 16 equal quarterly installments starting on
Relmada Therapeutics, Inc. reported that its Board of Directors approved amended and restated employment agreements for its executive officers on December 12, 2025. The updated contracts cover Chief Executive Officer Sergio Traversa, Chief Operating Officer Paul Kelly, Chief Financial Officer Maged Shenouda, and Chief Accounting and Compliance Officer Charles Ence, and are stated to become effective as of January 1, 2026. The company explains that, except for the revisions reflected in these new agreements, the material terms remain the same as those previously described in earlier SEC disclosures, and the complete agreements are filed as exhibits.
Relmada Therapeutics (RLMD) furnished an update and preliminary, unaudited quarterly financial results via a press release and scheduled a conference call to discuss them. The company plans to file complete unaudited financial statements and notes in its upcoming Form 10‑Q.
The press release was provided as Exhibit 99.1 and a refreshed corporate presentation as Exhibit 99.2. Under the furnished status, this information is not deemed filed under the Exchange Act except as specifically incorporated by reference. A conference call and webcast were set for November 13, 2025 at 4:30 PM ET to review the update and results.
Relmada Therapeutics (RLMD) filed its Q3 2025 10‑Q showing narrower losses and a refocused pipeline. Operating expenses fell to $10.3 million from $23.0 million a year ago, driving a net loss of $10.1 million versus $21.7 million. For the nine months, the net loss was $37.5 million, with operating cash outflow of $31.2 million. At September 30, cash was $1.38 million and short‑term investments were $12.50 million.
The company alleviated going‑concern uncertainty after closing an underwritten offering on November 5 for 40.14 million shares and 5.32 million pre‑funded warrants, generating approximately $94 million in net proceeds (before other expenses, excluding warrant exercises). Nasdaq confirmed minimum bid price compliance on September 15.
Pipeline shifted to two assets: NDV‑01 (intravesical gemcitabine/docetaxel) in Phase 2 for NMIBC showed a 92% “anytime” complete response among 25 evaluable patients and secured FDA alignment to pursue two Phase 3 studies, targeted to begin in H1 2026. Sepranolone was acquired for €3.0 million (with $2.756 million paid) and is expected to enter a Phase IIb study in Prader‑Willi Syndrome in H1 2026. Earlier esmethadone and psilocybin programs were terminated.
Relmada Therapeutics (RLMD) filed a Form 4 showing an insider purchase. The company’s Chief Financial Officer, Maged Shenouda, purchased 500,000 shares of common stock on 11/05/2025 at a price of $2.2 per share, coded “P” for purchase.
Following the transaction, beneficial ownership stood at 788,335 shares, reported as direct ownership. The filing reflects a personal share acquisition by a senior officer and updates the executive’s current holdings.
Relmada Therapeutics (RLMD) Form 4: An officer serving as CAO and COO reported an open-market purchase (transaction code P) of 136,000 shares of common stock on 11/05/2025 at $2.2 per share. Following the transaction, the reporting person beneficially owns 403,931 shares, held directly. The filing indicates a single reporting person and relates to Relmada Therapeutics, Inc.
Relmada Therapeutics (RLMD) insider activity: Chief Executive Officer and Director Sergio Traversa reported a purchase of 272,500 shares of Common Stock on 11/05/2025 at $2.2 per share (transaction code P).
Following the trade, he beneficially owns 1,272,500 shares, held directly. This Form 4 reflects an open-market or private purchase and updates his direct ownership position.
Relmada Therapeutics (RLMD) insider activity: Chief Operating Officer and Director Paul Kelly purchased 90,000 shares of common stock at $2.2 on 11/05/2025. Following the transaction, he directly beneficially owns 502,295 shares.
Relmada Therapeutics (RLMD) priced an underwritten equity offering of 40,142,000 common shares at $2.20 per share and pre-funded warrants to purchase up to 5,315,000 shares at $2.199 per warrant. The company expects approximately $100 million in net proceeds after underwriting discounts and expenses.
Pre-funded warrants are immediately exercisable at an exercise price of $0.001 per share, with a beneficial ownership cap of 9.99% (or 4.99% at the purchaser’s election). Company insiders, including the CEO, CFO, and other officers and directors, will purchase about $2.6 million of common stock at the same price as other investors.
Relmada plans to use proceeds for working capital and general corporate purposes, including clinical studies to gain regulatory approvals, further product development, licensing, and potential investments or acquisitions. The company agreed to customary indemnification provisions and 90-day restrictions on issuing additional equity or convertible securities.